Merck ’s Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in Bone Marrow Transplant Recipients, Highly Effective Through Week 24 Post-Transplant in Pivotal Phase 3 Study
Dateline City:
KENILWORTH, N.J. Letermovir Prophylaxis Associated with Lower All-Cause Mortality Through Week 24 Post-Transplant Company Plans to Submit New Drug Applications for Letermovir in U.S. and EU in 2017KENILWORTH, N.J.--(BUSINESS WIRE)--Merck& Co., Inc. (NYSE:MRK), known as MSD outside the United States and
Canada, today announced results of the pivotal Phase 3 clinical study of
letermovir, an investigational antiviral medicine for the prevention of
clinically-significant cytomegalovirus (CMV) infection in adult (18
years and older) CMV-seropositive recipients of an allogeneic
hematopoietic stem cell transplant (HSCT), also known as bone marrow
transplant (BMT).Language:
EnglishContact: MerckMedia:Pam Eisele, 267-305-3558Robert Consalvo, 908-236-1127orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NYSE
@Merckread more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK Letermovir MSD NYSE:MRK Source Type: news
More News: Bone Marrow Transplant | Cytomegalovirus | Merck | New Drug Applications | Pharmaceuticals | Stem Cell Therapy | Stem Cells | Study | Transplants